The cytotoxic activity and selectivity of the synthesized compounds against prostate cancer cell linea.
| Entry | 4a–n | PC-3 (IC50, μM) | PC-3 (IC50, μg ml−1) | VERO-B (IC50, μM) | SI* |
|---|---|---|---|---|---|
| 1 | 4a | ND | ND | ND | ND |
| 2 | 4b | 16.3 ± 2 | 7.5 | 26 | 1.6 |
| 3 | 4c | 11.8 ± 1.3 | 5.7 | 22 | 1.9 |
| 4 | 4d | 2 ± 0.125 | 1 | 9 | 4.5 |
| 5 | 4e | 15.5 ± 2 | 7.4 | 26 | 1.7 |
| 6 | 4f | 16.3 ± 2.5 | 8.6 | 30 | 1.8 |
| 7 | 4g | 16.3 ± 30 | 7.6 | 40 | 2.5 |
| 8 | 4h | 11.5 ± 11.5 | 5.4 | 18 | 1.6 |
| 9 | 4i | 7 ± 0.6 | 3.2 | 15 | 2.1 |
| 10 | 4j | 7 ± 0.2 | 3.7 | 20 | 2.9 |
| 11 | 4k | 9 ± 0.2 | 4.6 | 22 | 2.4 |
| 12 | 4l | 29 ± 3 | 13 | 60 | 2.1 |
| 13 | 4m | 26 ± 1.7 | 11.3 | 50 | 1.9 |
| 14 | 4n | 17 ± 2 | 9.4 | 40 | 2.4 |
| Positive control | Cisplatin | 5 ± 0.45 | 1.5 | 5 | 1 |
a
SI*: selectivity index, ND: not determine.